Recent Federal Circuit decisions have sown confusion among patent practitioners regarding core aspects of US patent law, including induced infringement, patent eligibility, written description, and enablement. Although the Supreme Court recently declined to provide needed clarity on patent eligibility in American Axle, it still has several opportunities in the coming months to address other critical issues for the LSPN community. In the meantime, the legislative and executive branches are embarking on their own efforts to enact legislation and regulations designed to clarify patent eligibility with respect to diagnostics, create a more predictable and powerful PTAB for petitioners and patent owners, and mandate closer collaboration between the USPTO and FDA. Topics to be covered in this session will include:
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office